COVID-19 Resources for Medical Professionals
Rutland Regional Medical Center has received supply of casirivimab/imdevimab injection (“the Regeneron cocktail”) through the FDA Emergency Use Authorization (EUA). We would like to make our supply available to eligible outpatients via primary care provider order. Casirivimab/imdevimab is a monoclonal antibody therapy for patients with mild to moderate COVID-19 who are at high risk of progressing to severe COVID-19 and/or hospitalization.
Eligible patients will be:
- COVID-19 positive with mild to moderate symptoms
- Have experienced for 10 days or less, with no new or increased oxygen demand
Additionally, patients will need to meet specific EUA use criteria described in the Casirivimab and Imbevimab Fact Sheet for Healthcare Providers (see download link below). We will also continue to offer bamlanivimab, another monoclonal antibody therapy for COVID-19 treatment, that we began administering at Rutland Regional in December 2020. At this time, there is no evidence to support the use of one monoclonal antibody treatment over another. If new evidence is released supporting the use of one therapy over another, we will communicate it.
If you have a patient that you would like considered for casirivimab/imdevimab or bamlanivimab IV therapy, please call Jon Prendergast, RN in our Infusion Center (802.772.2416) to determine if doses are available and to complete an intake questionnaire. Information on the Rutland Regional process is available in the below links, including a Fact Sheet for Patients, Parents and Caregivers which must be given to patients who agree to treatment.
We look forward to this opportunity to work with you and to make monoclonal antibody therapies available to your patients.